Interview: Current and future vaccine safety aspects
Posted: 4 March 2021 | Merck | No comments yet
Key requirements to ensure patient safety in the present-day development and production of viral vaccines, and the challenges going forward.
COVID-19 has drawn attention to the patient safety aspects of developing and manufacturing viral vaccines. This interview gives insights into the issues and obstacles faced by pharmaceutical companies, the current regulatory framework, and what Merck is doing to prepare itself and its customers for the inevitable next outbreak requiring the speedy development of a vaccine as well as streamlined and fast, but also safe, manufacture.
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Regulation & Legislation, Research & Development (R&D)
